Virexx Medical Corporation

Alberta Cancer Board

University Hospitals Board

Pharmanetics Incorporated

Imbiotechnologies Ltd

Virexx Medcial Corp.

Michael William Stewart

Antoine A Noujaim

Roland Henryk Person

Andrew R Shaw

Wai Sum Etches

Bruce D Hirsche, Legal Representative

Donald E Mahan

Philip A Gordon

Phillip A Gordon

Paul B Tiege

Irwin J Griffith

Antoine (deceased) Noujaim

The present invention relates generally to methods and compositions for treating a disease or condition by administering a first therapeutic protocol comprising targeting and delivering solid-phase platelet-dependent vascular occlusion agents, and administering at least one second therapeutic composition or method.

Methods of treatment using vascular occlusion in combination therapies

The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such as the vasculature of solid tumor masses; the platelet binding agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the formation of a platelet-mediated thrombus-causing vessel occlusion.

Compositions and methods for producing vascular occlusion

The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.

Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent

A platelet/leukocyte interaction assay method and reagent therefor are provided using the presence of a solid-phase stimulus, such as magnetic or non-magnetic particles or mixtures thereof, having bound to the surface thereof one or more ligands that interact directly with platelets, leukocytes or both, for providing a fast, reliable point-of-care assessment of platelet/leukocyte interaction.

Platelet/leukocyte interaction assay and reagent therefor

The invention provides a method for determining platelet function in a mammal comprising providing platelets from the mammal, contacting the platelets in suspension with at least one immobilised ECM protein or an effective fragment or analog thereof while applying to the platelets an effective mechanical stimulus for an effective period of time and determining the platelet activation produced. The invention provides a method for monitoring the efficacy of pharmacological agents affecting platelet function in vivo and in vitro.

Methods for determining platelet function

The invention provides phospholipid coated particles capable of specifically binding antiphospholipid antibodies and a method for preparing such particles. Methods are also provided for determining antiphospholipid antibodies in a serum or plasma. Also provided are methods for isolating antiphospholipid antibodies from a fluid and for raising specific antiphospholipid antibodies.

Methods for determining antiphospholipid antibodies

Methods for preparing phospholipid coated particles and for eliciting or

The invention provides a method for determining platelet function in a mammal comprising providing platelets from the mammal, contacting the platelets in suspension with at least one immobilised ECM protein or an effective fragment or analog thereof while applying to the platelets an effective mechanical stimulus for an effective period of time and determining the platelet activation produced. The invention also provides a method for detecting a bleeding disorder in a human. Further, the invention provides a method for monitoring the efficacy of pharmacological agents affecting platelet function in vivo.

Growing community of inventors

St. Albert, Canada

Michael William Stewart